Akero Therapeutics Initiates Phase 2b HARMONY Study of Efruxifermin (EFX) for the Treatment of NASH
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis
Chinook Receives Rare Pediatric Disease Designation from U.S. FDA for CHK-336 for Treatment of Primary Hyperoxaluria
Galaxy Medical CENTAURI PEF System to be Displayed at AF Symposium Recorded Case Presentation
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
Chinook Therapeutics Announces License Agreement with Morehouse School of Medicine for Development of Therapies in Kidney Diseases Disproportionately Affecting African Americans and Underserved Communities
ATP Forms ATP V With $1 Billion in New Capital Commitments
Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering
Stoke Therapeutics Announces Proposed Public Offering
Nereid Therapeutics Launches: ATP $50M Series A NewCo Co-Founded with Brangwynne, Pioneer of Biomolecular Condensates Field
Akero Therapeutics Reports Third Quarter 2020 Financial Results
Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates
Chinook Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
Akero Therapeutics Receives European Medicines Agency Priority Medicines (PRIME) Designation for Efruxifermin (EFX) in NASH
First Patients Treated with Galaxy Medical’s Centauri™ Pulsed Electric Field Cardiac Ablation System
Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome
Chinook Therapeutics Closes Merger with Aduro Biotech and Completes $115 Million Private Placement Financing
Aduro Biotech Stockholders Approve Merger Agreement with Chinook Therapeutics
Akero Therapeutics Completes Enrollment of Cohort of Cirrhotic (F4) Patients In Ongoing BALANCED Study
Akero Therapeutics To Continue Efruxifermin Development With Innovative Adaptive Phase 2b/3 Clinical Trial Design Based On FDA Written Guidance
Gala Therapeutics’ RheOx™ System Showcased at Virtual European Respiratory Society Congress
Results Published from Multicenter Study of Gala Therapeutics' Minimally Invasive RheOx™ System in Patients with Chronic Bronchitis
Preclinical Data on Stoke Therapeutics' STK-001 Published in Science Translational Medicine
Chinook Therapeutics Secures $106 Million Private Placement Financing to Advance Precision Medicines for Kidney Disease
STAT: 4 Questions for Neurology Startups as Venture Investors Pour Millions into the Field
Akero Therapeutics Reports Second Quarter 2020 Financial Results
Stoke Therapeutics Announces First Patient Dosed in MONARCH Study in Dravet Syndrome
Elstar Therapeutics and King’s College London Enter Immuno-Oncology Research Collaboration
Research Published in Cell Reports Medicine Highlights Potential of Akero Therapeutics' NASH Therapeutic Candidate
Akero Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
Stoke Therapeutics Announces Publication of Data in Nature Communications That Support Company’s Proprietary Approach to Addressing Severe Genetic Diseases by Precisely Upregulating Protein Expression
Apple Tree Partners Founds Nine Square Therapeutics to Pioneer Novel Treatments for Movement Disorders
Akero Announces Strongly Positive Histological Data Across All Efruxifermin Dose Groups in 16-Week Phase 2a BALANCED Study in NASH Patients
Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH
Apple Tree Partners Portfolio Company Corvidia Therapeutics to be Acquired by Novo Nordisk
Stoke Therapeutics Appoints Julie Anne Smith to its Board of Directors
Aduro Biotech and Chinook Therapeutics Announce Definitive Merger Agreement
Braeburn Submits Request for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Stoke Presents Preclinical Data That Demonstrate In-Vitro and In-Vivo Target Engagement and Protein Upregulation in OPA1 Protein Deficiency, the Primary Cause of the Most Common Inherited Optic Nerve Disorder
All AKR-001 Dose Groups Met Week 12 Efficacy Endpoints in NASH Phase 2a BALANCED Study
Corvidia Therapeutics Announces Publication in Science Translational Medicine of Strategy for Lowering Triglycerides Using a Mimetic Peptide
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Chinook Therapeutics Obtains Worldwide Rights from AbbVie to Atrasentan with Plans to Develop for the Treatment of Kidney Diseases
Syntimmune Antibody Therapeutic Candidate Reduces Immune Complexes Involved In Autoimmune Diseases
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
Stoke Therapeutics Presents Preclinical Data on Biodistribution, Target Engagement and Safety of STK-001 That Support Planned Clinical Development of STK-001 for Treatment of Dravet Syndrome
Stoke Therapeutics Presents Preclinical Data From Studies of STK-001 That Showed Improvements in Survival and Reductions in Seizure Frequency in a Mouse Model of Dravet Syndrome
FDA Approves Tula System For The Delivery Of Ear Tubes Under Local Anesthesia To Treat Ear Infection
Stoke Therapeutics to Present New Preclinical Data on STK-001 at the American Epilepsy Society Annual Meeting
​FDA Grants Braeburn’s Citizen Petition Allowing BRIXADI
​New Clinical Results from RheOxTM System for Chronic Bronchitis to be Presented at European Respiratory Society (ERS) International Congress
Gala Therapeutics Receives FDA Breakthrough Device Designation for the Minimally Invasive RheOx™ System for Chronic Bronchitis
Gala Therapeutics Receives CE Mark for its Minimally Invasive RheOx™ System for Chronic Bronchitis
Chinook Therapeutics Raises $65 Million Series A Financing to Advance Precision Medicines for Kidney Diseases
Stoke Therapeutics Granted FDA Orphan Drug Designation for STK-001, an Investigational New Treatment for Dravet Syndrome
U.S. District Court Orders FDA to Reconsider Application for Final Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Akero Therapeutics Announces Dosing of First Patient in Phase 2a Study of AKR-001 to Treat NASH (BALANCED)
Akero Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
Stoke Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Akero Therapeutics Announces Pricing of Initial Public Offering
Stoke Therapeutics Announces Pricing of Initial Public Offering
Stoke Therapeutics Appoints Jennifer Burstein to its Board of Directors
Braeburn Announces Publication of Phase 3 Study Results Showing Long-term Safety and Effectiveness of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Opioid Use Disorder
Akero Therapeutics Initiates Phase 2a Clinical Trial of Investigational Therapy AKR-001 for the Treatment of NASH
Initial Study of Gala's Minimally Invasive RheOx™ Device Demonstrates Positive Results for Chronic Bronchitis Patients
Akero Therapeutics Appoints Life Sciences Investment Banking Veteran Bill White as Chief Financial Officer and Head of Corporate Development
Akero Therapeutics Appoints Industry Veteran Jane Pritchett Henderson to Board of Directors
Stoke Therapeutics Appoints Industry Veteran Stephen Tulipano as Chief Financial Officer
Stoke Therapeutics to Present on First Disease-Modifying Therapies for Genetic Epilepsies at Cowen and Company Annual Health Care Conference
Behind the Seizure™ Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures
Gala Enrolls First Subject at Temple Lung Center as Part of the US Early Feasibility Trial of RheOx™ for Chronic Bronchitis in the United States
Akero Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
Corvidia Therapeutics to Present on Novel Anti-Inflammatory Therapy for Cardio-Renal Disease at J.P. Morgan Healthcare Conference
Stoke Therapeutics to Present on First Precision Treatments for Genetic Epilepsies at J.P. Morgan Healthcare Conference
Braeburn Announces Tentative FDA Approval of BRIXADI™ (buprenorphine) Extended-Release Injection for the Treatment of Moderate to Severe Opioid Use Disorder
Stoke Therapeutics Expands Senior Leadership Team, Adding Deep Expertise in Regulatory Affairs and Clinical Operations
Akero Therapeutics Announces $70 Million in New Financing
Akero Therapeutics Appoints Mark Iwicki to its Board of Directors
Stoke Therapeutics Presents Data Showing Single Dose of ASO Therapy Restores Normal Protein Levels in Animal Model of Genetic Epilepsy
Stoke Therapeutics to Present New Data on Lead Program at American Epilepsy Society's 2018 Annual Meeting
Gala Enrolls First Subjects in an Early Feasibility Study of RheOx™ for Chronic Bronchitis in the United States
Alexion Completes Acquisition Of Syntimmune
Stoke Therapeutics Announces $90 Million Series B Financing to Advance Novel Oligonucleotide Medicines
Akero Therapeutics Expands Leadership Team
Alexion to Acquire Syntimmune
CAM2038 Receives Positive CHMP Opinion for the Treatment of Opioid Dependence in Europe
Braeburn Announces Positive Top-line Phase 3 Results for CAM2038 in Chronic Low Back Pain Patients Previously on Long-term Daily Opioid Therapy
Gala Presents Positive Results from First-In-Human Clinical Trial of RheOx™ in Chronic Bronchitis at the European Respiratory Society
Stoke Therapeutics Appoints Biotech Veteran Arthur Tzianabos, Ph.D. to Board of Directors
Syntimmune Announces FDA Orphan Drug Designation for SYNT001 in Treatment of Pemphigus
Andrew Cheng, MD, PhD Joins Akero Therapeutics as President and Chief Executive Officer
Data From First-In-Human RheOx™ Bronchial Rheoplasty Trial to be Presented at the European Respiratory Society
Braeburn Announces PDUFA Date for CAM2038 for the Treatment of Opioid Use Disorder
Gala Therapeutics Receives FDA IDE Approval for a US Early Feasibility Study of Its RheOx™ System to Treat Chronic Bronchitis
Syntimmune Strengthens Leadership Team with Appointment of Chief Medical Officer
Akero Therapeutics Closes $65 Million Series A Financing to Advance New Treatments for Serious Metabolic Diseases
Braeburn Appoints Richard Malamut, M.D. as Chief Medical Officer
Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence
Braeburn Resubmits New Drug Application for CAM2038 for Opioid Use Disorder
Syntimmune Announces Positive Preliminary Results from Clinical Proof-of-Concept Trial of SYNT001 in Pemphigus Vulgaris and Foliaceus
Startup seeks answers to insidious form of epilepsy
Braeburn Announces Publication of Positive Phase 3 Results For Long-Acting Buprenorphine For Treatment Of Opioid Use Disorder in JAMA Internal Medicine
Stoke Therapeutics to Present Research Supporting Its Novel Approach to Oligonucleotide Mediated Gene Up-Regulation at TIDES and ASGCT Conferences
Corvidia Therapeutics Secures $60 Million in Series B Funding to Accelerate Clinical Work
Syntimmune Appoints Andrew Cheng, M.D., Ph.D., to Board of Directors, Bolstering Clinical Development Expertise
Knight Therapeutics Announces Canadian Regulatory Approval for PROBUPHINE™ for Opioid Drug Dependence
Stoke Therapeutics Expands Leadership Team, Building on Deep Expertise in Oligonucleotide Chemistry and Rare Disease Research and Development
Braeburn Launches Brave Action
Corvidia Therapeutics Appoints Marc de Garidel as Chief Executive Officer
Syntimmune to Present Clinical Data on Lead Program SYNT001 at Plenary Session of International Investigative Dermatology Conference
Tusker Medical Announces First Patient Enrollment in Pivotal Clinical Trial Assessing In-Office Pediatric Tympanostomy Tube Placement
Braeburn Announces Completion of $110 Million Financing
Syntimmune Appoints Jean-Paul Kress, M.D., as President and Chief Executive Officer
Syntimmune Announces Clinical Data from First-in-Human Trial of Lead Candidate SYNT001
Braeburn Announces FDA Advisory Committee Recommends Approval of CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder
Braeburn CEO Participates in U.S. Department of Health and Human Services Secretarial Roundtable Discussion on Opioids
Braeburn Participates in President’s Commission Meeting on Combating Drug Addiction and the Opioid Crisis
Braeburn Announces FDA Acceptance with Priority Review of New Drug Application for CAM2038 Buprenorphine Depot for the Treatment of Opioid Use Disorder
Braeburn and Camurus Announce Submission of NDA for Long-Acting Buprenorphine (CAM2038) for Opioid Use Disorder
Phase 2 Trial Demonstrates Long-acting Buprenorphine Blocks Opioid Effects and Suppresses Withdrawal Symptoms in Adults with Opioid Use Disorder
Syntimmune Closes $50 Million Series B Financing Led By Apple Tree Partners
Braeburn Pharmaceuticals and Camurus Announce Presentations of Pivotal Clinical Study Data of Long-acting Buprenorphine
Braeburn Pharmaceuticals and Knight Therapeutics Announce Filing of New Drug Submission for PROBUPHINE® in Canada for Opioid Drug Dependence
Braeburn Pharma Keeps Up with Competitors with Long-Acting Risperidone for Schizophrenia
Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Results from Long-term Phase 3 Safety Study of CAM2038
Braeburn Pharmaceuticals Achieves Primary Endpoint in Pivotal Phase 2/3 Study of BB0817, Risperidone 6-month Implant for Treatment of Schizophrenia
Syntimmune Announces Breakthrough Results of FcRn Inhibition Published in PNAS
Fast Company Honors Braeburn Pharmaceuticals as a Top Ten Most Innovative Company in Biotech
Braeburn Pharmaceuticals’ Probuphine® Implant Receives J-Code by Centers for Medicare & Medicaid Services
Braeburn Pharmaceuticals and CEO Behshad Sheldon Win Stevie Awards for Best New Product or Service and Female Executive of the Year
Syntimmune Announces Appointment of David De Graaf, Ph.D., as CEO and Election of Burt Adelman, M.D., to the Board as Company’s Clinical Program for Lead Candidate SYNT001 Continues to Advance
Braeburn Pharmaceuticals and Camurus Announce Positive Top-line Phase 3 Results for Long-acting Buprenorphine (CAM2038) for Treatment of Opioid Addiction
​ Probuphine® Wins Popular Science’s “Best of What’s New” Award
Braeburn Pharmaceuticals and Camurus Expand Collaboration and License Agreement to Include New Combination Product for Pain and Nausea
Braeburn Pharmaceuticals and Camurus announce the presentation of new data from clinical studies of long-acting buprenorphine
Braeburn Pharmaceuticals and Camurus Enroll First Patients in a Phase 3 Efficacy Trial of CAM2038 for Treatment of Chronic Low Back Pain
HeartWare Receives FDA Approval To Enroll Supplemental Patient Cohort In Destination Therapy Trial
Medtronic Completes Acquisition of HeartWare International
Apple Tree Bankrolls Johnson & Johnson Spinout Tusker Medical
Braeburn Pharmaceuticals Announces Probuphine Data Published in the Journal of the American Medical Association
Medtronic to Expand Heart Failure Portfolio with Acquisition of HeartWare International
FDA approves first buprenorphine implant for treatment of opioid dependence
Syntimmune Secures Second Tranche of $26 Million Series A Financing
Braeburn and Camurus Announce Initiation of a Phase 2 Study in Opioid Dependent Patients with Moderate to Severe Chronic Pain
Corvidia Therapeutics Raises $26M in a Series A Financing, Led by Sofinnova Partners and Apple Tree Partners
Braeburn Pharmaceuticals and Knight Therapeutics Announce Canadian Sublicense Agreement for PROBUPHINE®
Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce FDA Advisory Committee Recommends Approval of Probuphine, First 6-Month Implant to Treat Opioid Addiction
Camurus AB: Braeburn Pharmaceuticals and Camurus Announces Start of Phase 3 Trial of Long-Acting Buprenorphine Treatments for Opioid Dependence
Titan Pharmaceuticals and Braeburn Pharmaceuticals Announce Date of FDA Advisory Committee Review of Probuphine for Opioid Addiction
FDA Grants Fast Track Designation for Development of CAM2038, Long-Acting Buprenorphine Injections to Treat Opioid Addiction
FDA Accepts Braeburn’s Resubmission of Probuphine NDA for Review
Braeburn Pharmaceuticals Commends HHS Secretary Burwell for Initiative to Expand Access to Medication-Assisted Treatment for Opioid Addiction
Abbott Enters Agreement to Purchase Tendyne Holdings
Braeburn Pharmaceuticals Reports Positive Results From Phase 3 Study of Probuphine for Opioid Addiction
Tendyne Announces First Patient Enrolled in US Trans-Catheter Mitral Valve Replacement Trial
Tendyne Raises $25 Million in Series C
The Tendyne Transcatheter Mitral Valve Implantation system (TMVI) was successfully implanted in the first patient of the Tendyne Feasibility Study
Tendyne Announces Successful First Human Implants of Transcatheter Mitral Valve Implant
Braeburn Pharmaceuticals’ Probuphine® Study Hits Enrollment Milestone
Titan Pharmaceuticals Announces Agreement in Principle on Path Forward for Probuphine Clinical Study
Titan Pharmaceuticals Announces $5 Million Equity Investment and Restructuring of Probuphine Partnership
Frank E. Young, Former FDA Commissioner, Joins Braeburn Pharmaceuticals as EVP, Clinical and Regulatory Affairs
Titan Pharmaceuticals Announces Publication of Phase 3 Probuphine Data in Additiction
HeartWare Presentation At The Canaccord Genuity 2013 Annual Growth Conference To Be Webcast
HeartWare International Reports $50.8 Million In Second Quarter 2013 Revenue; 75% Increase From Second Quarter Of 2012
HeartWare Receives Conditional Approval From FDA to Enroll Supplemental Patient Cohort in Destination Therapy Trial
HeartWare International Reports $49.2 Million In First Quarter 2013 Revenue; 87% Increase From First Quarter Of 2012
Titan Pharmaceuticals Announces FDA Advisory Committee Recommends Approval of Probuphine®
Titan announces date of FDA Advisory Committee Review of PROBUPHINE® for the Treatment of Opioid Dependence
HeartWare International, Inc. Announces Pricing of Public Offering of Common Stock
HeartWare International Announces Preliminary Fourth Quarter 2012 Revenues
Probuphine® Receives FDA Priority Review Designation for Adult Patients with Opioid Dependence
Titan Pharmaceuticals Licenses Exclusive Probuphine® Commercialization Rights in U.S. and Canada to Braeburn Pharmaceuticals
HeartWare Receives FDA Approval for HeartWare Ventricular Assist System as a Bridge to Heart Transplantation for Patients with Advanced Heart Failure
HeartWare Completes Acquisition Of World Heart Corporation
FDA Advisory Committee Votes in Favor of HeartWare® Ventricular Assist System as Bridge to Transplant for Patients With End-Stage Heart Failure
HeartWare International Expands Intellectual Property and Technology Portfolio Through Definitive Agreement to Acquire World Heart Corporation for US$8 Million
FDA Grants Accelerated Approval of ISTODAX(R) As Treatment for Patients with Peripheral T-Cell Lymphoma Who Have Received at Least One Prior Therapy
HeartWare Reports Additional Data from Bridge-to-Transplant Clinical Trial and Continued Access Patients
HeartWare International Receives Approval From the Therapeutic Goods Administration (TGA) in Australia
FDA Grants Priority Review For ISTODAX(R) sNDA For Treatment of Progressive or Relapsed PTCL
HeartWare Receives Third Patient Allotment From FDA - Authorizing 94 Additional Patients - Under Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
HeartWare Files PMA Application for FDA Approval of the HeartWare(R) Ventricular Assist System for a Bridge-to-Transplant Indication
HeartWare International, Inc. Announces Completion of Concurrent Public Offerings of Convertible Senior Notes and Common Stock
HeartWare International, Inc. Announces Concurrent Public Offerings of Convertible Senior Notes and Common Stock
HeartWare 5-Ounce Pump Extends Lives in Heart Failure Patients
HeartWare Achieves Primary Endpoint with 92% Success in Pivotal Bridge-to-Transplant Clinical Trial
HeartWare Receives Conditional FDA Approval to Commence Pivotal Destination Therapy Clinical Trial in the U.S.
HeartWare Data From First 100 Patients in International Clinical and Commercial Experience Shows 90% Survival at 180 Days
HeartWare Receives FDA Approval of Continued Access Protocol for Pivotal U.S. Bridge-to-Transplant Clinical Trial
HeartWare Announces Early Conclusion of Enrollment for U.S. Bridge-to-Transplant Clinical Trial
HeartWare International, Inc. Announces Completion of Public Offering of Common Stock
HeartWare International, Inc. Announces Commencement of Public Offering of Common Stock
Celgene to Acquire Gloucester Pharmaceuticals
FDA Approves Gloucester Pharmaceuticals’ ISTODAX® for Patients with Cutaneous T-cell Lymphoma
FDA Advisory Committee Recommends Gloucester Pharmaceuticals’ Romidepsin for Approval for Cutaneous T-cell Lymphoma
Gloucester raises $29 million
HeartWare International Surpasses 50 Implants In The US
HeartWare International, Inc. Closes US$60 Million Financing